Skip to content

Bausch + Lomb BLCO Remainder of Fiscal Year 2025

Remainder of Fiscal Year 2025 at other companies

The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
Solventum logo
SolventumSOLV
PBH
Prestige Consumer HealthcarePBH
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
Viatris logo
ViatrisVTRS

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Operating income$33.0M+140%
Net income-$71.0M+66.5%
EPS (diluted)-$0.20+66.7%

Balance sheet

See full
Cash & equivalents$279.0M+29.8%
Total debt$5.0B+4.3%
Total equity$6.4B+0.3%
Total assets$13.8B+2.6%

Cash flow

See full
Operating cash flow$32.0M+228%
CapEx$100.0M-9.1%
Free cash flow-$68.0M+49.6%

Valuation

See full
Market cap$5.43B+10.2%

Profitability

See full
Operating margin4.4%+2.9pp
Net margin-4.2%-1.3pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-3.4%-0.9pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's remainder of fiscal year 2025.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch + Lomb's remainder of fiscal year 2025?
Bausch + Lomb (BLCO) reported remainder of fiscal year 2025 of $168M in Q1 2026.
How has Bausch + Lomb's remainder of fiscal year 2025 changed year-over-year?
Bausch + Lomb's remainder of fiscal year 2025 decreased by 7.7% year-over-year, from $182M to $168M.